Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica Red Brewer

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Cancer Cell|March 3, 2009
EpCAM: another surface-to-nucleus missileGraham Carpenter, Monica Red Brewer
Cancer Discovery|February 13, 2013
Maximizing the benefits of off-target kinase inhibitor activityMonica Red Brewer, William Pao
Breast Cancer Research and Treatment|November 3, 2016
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA <sup>H1047R</sup> in HER2/ER-positive breast cancerFeixiong Cheng, Junfei Zhao, Ariella B Hanker, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 11, 2013
Mechanism for activation of mutated epidermal growth factor receptors in lung cancerMonica Red Brewer, Cai-Hong Yun, Darson Lai, et al.
Molecular Cell|June 30, 2009
The juxtamembrane region of the EGF receptor functions as an activation domainMonica Red Brewer, Sung Hee Choi, Diego Alvarado, et al.
Cancer Discovery|August 20, 2015
EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to AfatinibJean-Nicolas Gallant, Jonathan H Sheehan, Timothy M Shaver, et al.
Nature Communications|March 3, 2021
Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targetingZhenfang Du, Benjamin P Brown, Soyeon Kim, et al.
The Journal of Clinical Investigation|November 18, 2014
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancerLuis J Schwarz, Emily M Fox, Justin M Balko, et al.
Cancer Cell|June 25, 2021
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivityAriella B Hanker, Benjamin P Brown, Jens Meiler, et al.
Journal of the National Cancer Institute|October 24, 2017
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand OverexpressionLuis J Schwarz, Katherine E Hutchinson, Brent N Rexer, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cancer Cell|March 3, 2009
EpCAM: another surface-to-nucleus missileGraham Carpenter, Monica Red Brewer
Cancer Discovery|February 13, 2013
Maximizing the benefits of off-target kinase inhibitor activityMonica Red Brewer, William Pao
Breast Cancer Research and Treatment|November 3, 2016
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA <sup>H1047R</sup> in HER2/ER-positive breast cancerFeixiong Cheng, Junfei Zhao, Ariella B Hanker, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 11, 2013
Mechanism for activation of mutated epidermal growth factor receptors in lung cancerMonica Red Brewer, Cai-Hong Yun, Darson Lai, et al.
Molecular Cell|June 30, 2009
The juxtamembrane region of the EGF receptor functions as an activation domainMonica Red Brewer, Sung Hee Choi, Diego Alvarado, et al.
Cancer Discovery|August 20, 2015
EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to AfatinibJean-Nicolas Gallant, Jonathan H Sheehan, Timothy M Shaver, et al.
Nature Communications|March 3, 2021
Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targetingZhenfang Du, Benjamin P Brown, Soyeon Kim, et al.
The Journal of Clinical Investigation|November 18, 2014
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancerLuis J Schwarz, Emily M Fox, Justin M Balko, et al.
Cancer Cell|June 25, 2021
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivityAriella B Hanker, Benjamin P Brown, Jens Meiler, et al.
Journal of the National Cancer Institute|October 24, 2017
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand OverexpressionLuis J Schwarz, Katherine E Hutchinson, Brent N Rexer, et al.
Pageof 2